Clustering data with hclust algorithm for (Study ST000668)

(Analysis AN001022)
MetaboliteStructureF1F2F3F4F5F6
plasmenyl-PE 38:1; [M-H]-@8.31ME1827261.070.505.360.830.150.19
PC 38:4; [M-Ac-H]-@5.56ME1826610.613.060.251.730.540.62
plasmenyl-PE 38:2; [M-H]-@7.96ME1827270.931.722.631.050.480.33
PC 30:0; [M-Ac-H]-@6.11ME1826330.840.712.210.831.320.82
PE 32:1; [M-H]-@6.29ME1826740.680.552.231.261.031.36
PC 32:1; [M-Ac-H]-@6.26ME1826360.760.781.771.910.890.81
lysoPE 22:4; [M-H]-@1.93ME1827140.921.101.681.390.840.64
lysoPE 22:5; [M-H]-@1.61ME1827150.911.001.591.370.830.83
lysoPE 20:3; [M-H]-@1.67ME1827110.900.971.541.630.670.89
lysoPE 20:5; [M-H]-@1.07ME1827130.920.931.331.770.760.74
PC 28:0; [M-Ac-H]-@5.41ME1826320.860.781.351.021.740.51
PC 30:1; [M-Ac-H]-@5.58ME1826340.780.851.241.001.660.82
PE 40:6; [M-H]-@6.94ME1826921.130.610.860.621.091.24
CL 82:13; [M-2H](2-)@6.39ME1826191.280.550.730.480.871.34
PE 38:6; [M-H]-@6.28ME1826901.120.620.570.561.081.48
PE 40:7; [M-H]-@6.43ME1826931.210.700.560.450.941.44
plasmenyl-PE 40:4; [M-H]-@7.84ME1827330.811.691.161.150.820.92
PE 40:8; [M-H]-@5.97ME1826941.230.651.190.670.881.01
lysoPE 18:1; [M-H]-@1.85ME1827091.020.981.310.960.651.26
PG 36:2; [M-H]-@5.99ME1826971.100.611.500.960.751.13
plasmenyl-PE 34:3; [M-H]-@6.35ME1827201.061.081.931.020.610.74
lysoPE 16:0; [M-H]-@1.69ME1827071.040.941.960.960.800.74
lysoPE 18:0; [M-H]-@2.50ME1827081.051.021.810.820.890.73
PC 32:0; [M-Ac-H]-@6.79ME1826350.980.841.590.970.970.95
PC 38:2; [M-Ac-H]-@7.71ME1826580.970.961.471.000.831.08
PC 35:4; [M-Ac-H]-@6.05ME1826471.001.001.440.801.000.93
PE 40:5; [M-H]-@7.16ME1826910.980.811.530.771.160.96
PC 33:0; [M-Ac-H]-@6.98ME1826380.900.901.741.041.130.79
PC 33:1; [M-Ac-H]-@6.57ME1826390.870.721.550.981.330.95
CL 70:1; [M-2H](2-)@6.86ME1826150.950.641.130.951.261.11
PE 34:1; [M-H]-@6.89ME1826760.900.650.921.141.261.18
PE 36:4; [M-H]-@6.28ME1826840.990.670.831.041.330.96
PC 32:2; [M-Ac-H]-@5.78ME1826371.010.881.240.981.190.73
PC 35:2; [M-Ac-H]-@6.73ME1826461.060.941.260.901.170.63
CL 70:5; [M-2H](2-)@6.06ME1826161.110.781.231.161.010.64
PE 34:3; [M-H]-@6.06ME1826781.180.631.041.190.970.69
PC 34:4; [M-Ac-H]-@5.65ME1826441.040.850.940.981.230.80
PE 37:4; [M-H]-@6.71ME1826861.130.751.020.851.130.81
PE 34:2; [M-H]-@6.43ME1826771.050.660.991.161.240.74
PE 35:2; [M-H]-@6.72ME1826791.070.541.151.071.160.87
plasmenyl-PE 36:5; [M-H]-@6.35ME1827251.050.830.591.430.950.93
PI 36:4; [M-H]-@5.12ME1827010.910.810.821.570.951.09
PI 38:3; [M-H]-@6.04ME1827030.861.030.941.431.001.04
PC 36:1; [M-Ac-H]-@7.55ME1826480.881.001.311.330.960.95
PC 35:1; [M-Ac-H]-@7.25ME1826450.910.841.251.121.131.00
PC 34:1; [M-Ac-H]-@6.85ME1826410.910.781.191.261.091.01
PC 38:3; [M-Ac-H]-@7.31ME1826590.950.851.121.261.010.98
PC 40:4; [M-Ac-H]-@7.52ME1826680.910.831.121.281.070.99
PI 38:5; [M-H]-@5.26ME1827050.960.901.111.180.911.10
PC 34:3; [M-Ac-H]-@5.90ME1826430.950.991.131.240.940.94
PC 38:5; [M-Ac-H]-@6.50ME1826620.951.001.061.250.960.94
PE 38:3; [M-H]-@7.26ME1826870.950.701.251.110.971.19
PI 34:1; [M-H]-@5.59ME1826980.800.771.311.341.031.25
PC 36:5; [M-Ac-H]-@5.80ME1826520.930.811.141.630.830.94
PE 36:5; [M-H]-@6.05ME1826850.870.581.371.590.891.14
plasmenyl-PE 34:0; [M-H]-@7.27ME1827170.911.221.180.790.981.18
FFA(22:3)ME1826260.991.271.120.670.981.03
FFA(24:1)ME1826281.001.341.040.680.841.14
plasmenyl-PE 36:1; [M-H]-@7.80ME1827211.001.310.950.880.801.09
FFA(24:2)ME1826291.081.320.940.680.900.93
PC 39:4; [M-Ac-H]-@7.26ME1826661.031.390.970.760.910.91
FFA(24:0)ME1826271.001.461.150.900.830.82
PG 36:0; [M-H]-@6.80ME1826960.971.221.141.050.801.03
FFA(Arachidonic acid)ME1826310.961.341.130.970.890.92
lysoPE 20:4; [M-H]-@1.38ME1827121.001.311.061.040.810.91
PI 34:2; [M-H]-@5.13ME1826991.011.140.861.210.781.01
plasmenyl-PE 36:3; [M-H]-@6.91ME1827230.971.180.871.130.891.02
PC 37:2; [M-Ac-H]-@7.38ME1826541.001.031.101.090.781.12
PE 34:0; [M-H]-@7.31ME1826751.011.051.030.920.981.01
PG 34:0; [M-H]-@6.20ME1826950.991.021.010.961.001.04
FFA(20:0)ME1826201.031.021.111.000.930.93
PI 37:4; [M-H]-@5.48ME1827021.001.131.090.960.891.01
lysoPE 18:2; [M-H]-@1.40ME1827101.001.241.351.280.780.66
PC 34:0; [M-Ac-H]-@7.44ME1826400.921.231.521.020.930.83
FFA(22:0)ME1826230.991.241.291.030.860.83
plasmenyl-PE 38:3; [M-H]-@7.58ME1827280.971.131.370.970.980.82
FFA(24:3)ME1826301.221.201.020.760.600.90
CL 74:7; [M-2H](2-)@6.13ME1826181.210.951.270.840.710.80
PE 36:0; [M-H]-@7.92ME1826801.121.111.330.760.770.88
FFA(22:1)ME1826241.071.331.470.800.750.76
FFA(22:2)ME1826251.101.231.460.510.840.89
PC 42:4; [M-Ac-H]-@8.30ME1826721.091.251.230.660.920.83
plasmenyl-PE 40:6; [M-H]-@7.22ME1827351.081.260.640.910.701.17
plasmenyl-PE 42:5; [M-H]-@7.92ME1827360.931.520.650.780.921.22
plasmenyl-PE 38:6; [M-H]-@6.60ME1827321.110.970.450.751.071.15
PI 38:6; [M-H]-@5.03ME1827061.160.640.590.891.041.13
PE 36:3; [M-H]-@6.57ME1826831.090.820.671.000.941.14
PC 36:6; [M-Ac-H]-@5.57ME1826531.020.860.710.961.051.19
PE 38:5; [M-H]-@6.54ME1826891.020.760.770.931.101.19
PC 42:5; [M-Ac-H]-@7.72ME1826731.090.850.700.801.141.03
PE 38:4; [M-H]-@6.98ME1826881.030.800.760.961.181.03
PC 40:7; [M-Ac-H]-@6.33ME1826700.990.990.780.791.041.29
PC 40:6; [M-Ac-H]-@6.87ME1826691.140.820.630.671.081.15
PC 38:6; [M-Ac-H]-@6.13ME1826641.080.800.710.761.061.23
PC 38:6; [M-Ac-H]-@6.31ME1826631.080.800.710.761.061.23
plasmenyl-PE 36:2; [M-H]-@7.36ME1827221.031.220.890.920.950.94
plasmenyl-PE 34:1; [M-H]-@7.21ME1827181.051.000.760.911.001.05
plasmenyl-PE 40:5; [M-H]-@7.39ME1827341.111.060.720.881.030.85
plasmenyl-PE 38:4; [M-H]-@7.27ME1827291.061.150.730.880.990.97
plasmenyl-PE 38:4; [M-H]-@7.37ME1827301.061.150.730.880.990.97
PC 37:5; [M-Ac-H]-@6.19ME1826570.961.020.651.141.160.95
PC 38:4; [M-Ac-H]-@6.92ME1826600.990.931.021.041.060.97
PC 36:2; [M-Ac-H]-@7.03ME1826491.040.880.900.951.031.05
PC 36:3; [M-Ac-H]-@6.55ME1826501.020.890.831.071.041.02
PC 34:2; [M-Ac-H]-@6.34ME1826421.000.970.891.031.031.03
plasmenyl-PE 34:2; [M-H]-@6.76ME1827190.950.960.941.061.061.07
PC 36:4; [M-Ac-H]-@6.22ME1826510.950.950.891.041.200.96
PC 37:3; [M-Ac-H]-@6.91ME1826550.921.000.890.931.171.11
PE 36:2; [M-H]-@7.03ME1826821.050.850.781.200.941.02
CL 74:1; [M-2H](2-)@7.51ME1826171.010.960.691.060.921.20
PE 36:1; [M-H]-@7.48ME1826810.970.920.671.080.991.27
plasmenyl-PE 36:4; [M-H]-@6.69ME1827240.911.000.671.131.011.28
PC 40:8; [M-Ac-H]-@5.89ME1826710.911.000.921.190.971.15
PI 38:4; [M-H]-@5.79ME1827040.930.970.831.111.061.12
plasmenyl-PE 38:5; [M-H]-@6.77ME1827310.951.020.741.120.991.17
PC 38:7; [M-Ac-H]-@5.61ME1826651.040.870.851.030.901.16
PI 36:2; [M-H]-@5.81ME1827001.021.010.831.090.911.07
PC 37:4; [M-Ac-H]-@6.67ME1826560.961.160.890.761.290.88
FFA(20:1)ME1826211.141.170.690.501.080.97
PC 39:6; [M-Ac-H]-@6.54ME1826671.181.320.660.471.020.84
FFA(20:2)ME1826221.201.110.850.541.010.83
lysoPE 22:6; [M-H]-@1.33ME1827161.151.140.830.740.920.87

Factors:

F1Diet intervention:Baseline | Gender:female
F2Diet intervention:Baseline | Gender:male
F3Diet intervention:Overfeeding-2 weeks | Gender:female
F4Diet intervention:Overfeeding-2 weeks | Gender:male
F5Diet intervention:Saturated Fatty Acid | Gender:female
F6Diet intervention:Unsaturated Fatty Acid | Gender:female
Data matrix
  logo